Roland Steck

Roland Steck

Auto-generated profile, based on publicly available information

Roland Steck

Queensland University of Technology

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2013 in Bone Research
Verified
Journal Article
Closed access
JHJan Henkel
Jan Henkel
MWMaria Woodruff
Maria Woodruff
DEDevakara Rao Epari
Devakara Rao Epari
RSRoland Steck
Roland Steck
VGVaida Glatt
Vaida Glatt
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher

1 December 2014 in The American Journal of Pathology
Verified
Journal Article
Closed access
LRLiza J. Raggatt
Liza J. Raggatt
MWMartin E. Wullschleger
Martin E. Wullschleger
KAKylie A. Alexander
Kylie A. Alexander
AWAndy C.K. Wu
Andy C.K. Wu
SMSusan M. Millard
Susan M. Millard
APAllison R. Pettit
Allison R. Pettit

10 February 2012 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MRMerja Ruutu
Merja Ruutu
GTGethin Thomas
Gethin Thomas
RSRoland Steck
Roland Steck
MDMariapia A. Degli‐Esposti
Mariapia A. Degli‐Esposti
MZMartin Sebastian Zinkernagel
Martin Sebastian Zinkernagel
RTRanjeny Thomas
Ranjeny Thomas
Objective: The spondylarthritides (SpA), including ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis, and arthritis associated with inflammatory bowel disease, cause chronic inflammation of the large peripheral and axial joints, eyes, skin, ileum, and colon. Genetic studies reveal common candidate genes for AS, PsA, and Crohn's disease, including IL23R, IL12B, STAT3, and CARD9, all of which are associated with interleukin‐23 (IL‐23) signaling downstream of the dectin 1 β‐glucan receptor. In autoimmune‐prone SKG mice with mutated ZAP‐70, which attenuates T cell receptor signaling and increases the autoreactivity of T cells in the peripheral repertoire, IL‐17–dependent inflammatory arthritis developed after dectin 1–mediated fungal infection. This study was undertaken to determine whether SKG mice injected with 1,3‐β‐glucan (curdlan) develop evidence of SpA, and the relationship of innate and adaptive autoimmunity to this process.Methods: SKG mice and control BALB/c mice were injected once with curdlan or mannan. Arthritis was scored weekly, and organs were assessed for pathologic features. Anti–IL‐23 monoclonal antibodies were injected into curdlan‐treated SKG mice. CD4+ T cells were transferred from curdlan‐treated mice to SCID mice, and sera were analyzed for autoantibodies.Results: After systemic injection of curdlan, SKG mice developed enthesitis, wrist, ankle, and sacroiliac joint arthritis, dactylitis, plantar fasciitis, vertebral inflammation, ileitis resembling Crohn's disease, and unilateral uveitis. Mannan triggered spondylitis and arthritis. Arthritis and spondylitis were T cell– and IL‐23–dependent and were transferable to SCID recipients with CD4+ T cells. SpA was associated with collagen‐ and proteoglycan‐specific autoantibodies.Conclusion: Our findings indicate that the SKG ZAP‐70W163C mutation predisposes BALB/c mice to SpA, resulting from innate and adaptive autoimmunity, after systemic β‐glucan or mannan exposure.

1 October 2011 in Bone
Verified
Journal Article
Closed access
THT. Histing
T. Histing
PGP. Garcia
P. Garcia
JHJ.H. Holstein
J.H. Holstein
MKM. Klein
M. Klein
RMR. Matthys
R. Matthys
MMM D Menger
M D Menger

1 April 2014 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
ABA. Berner
A. Berner
MWMaria Woodruff
Maria Woodruff
CLC.X.F. Lam
C.X.F. Lam
MAM.T. Arafat
M.T. Arafat
SSS. Saifzadeh
S. Saifzadeh
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher

1 February 2010 in Tissue Engineering Part B: Reviews
Verified
Journal Article
Closed access
JRJohannes C. Reichert
Johannes C. Reichert
DEDevakara Rao Epari
Devakara Rao Epari
MWMartin E. Wullschleger
Martin E. Wullschleger
SSSiamak Saifzadeh
Siamak Saifzadeh
RSRoland Steck
Roland Steck
Dietmar Werner HutmacherDietmar Werner Hutmacher
Dietmar Werner Hutmacher
Currently, well-established clinical therapeutic approaches for bone reconstruction are restricted to the transplantation of autografts and allografts, and the implantation of metal devices or ceramic-based implants to assist bone regeneration. Bone grafts possess osteoconductive and osteoinductive properties; however, they are limited in access and availability and associated with donor-site morbidity, hemorrhage, risk of infection, insufficient transplant integration, graft devitalization, and subsequent resorption resulting in decreased mechanical stability. As a result, recent research focuses on the development of alternative therapeutic concepts. The field of tissue engineering has emerged as an important approach to bone regeneration. However, bench-to-bedside translations are still infrequent as the process toward approval by regulatory bodies is protracted and costly, requiring both comprehensive in vitro and in vivo studies. The subsequent gap between research and clinical translation, hence, commercialization, is referred to as the “Valley of Death” and describes a large number of projects and/or ventures that are ceased due to a lack of funding during the transition from product/technology development to regulatory approval and subsequently commercialization. One of the greatest difficulties in bridging the Valley of Death is to develop good manufacturing processes and scalable designs and to apply these in preclinical studies. In this article, we describe part of the rationale and road map of how our multidisciplinary research team has approached the first steps to translate orthopedic bone engineering from bench to bedside by establishing a preclinical ovine critical-sized tibial segmental bone defect model, and we discuss our preliminary data relating to this decisive step.